Media stories about Lipocine (NASDAQ:LPCN) have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lipocine earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.5002463158813 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Zacks: Analysts Expect Lipocine Inc. (LPCN) to Post -$0.27 Earnings Per Share (americanbankingnews.com)
- Lipocine Announces Financial and Operational Results for the Third … – GlobeNewswire (press release) (globenewswire.com)
- Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017 (finance.yahoo.com)
- Lipocine reports 3Q loss (finance.yahoo.com)
A number of research firms recently issued reports on LPCN. Roth Capital set a $38.00 target price on Lipocine and gave the stock a “buy” rating in a research note on Thursday, August 10th. ValuEngine cut Lipocine from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Finally, Canaccord Genuity set a $11.00 target price on Lipocine and gave the stock a “buy” rating in a research note on Monday, August 7th.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/14/lipocine-lpcn-earning-somewhat-positive-press-coverage-report-shows.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.